Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.70 |
| ▸ | KDR | P35968 | 4/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.65 |
| ▸ | INSR | P06213 | 1/20 | 0.65 |
| ▸ | FBP1 | P09467 | 1/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.65 |
| ▸ | FLT4 | P35916 | 1/20 | 0.65 |
| ▸ | CLK1 | P49759 | 1/20 | 0.65 |
| ▸ | TEK | Q02763 | 1/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.65 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623520 | 1.00 | EGFR (0.70) | EGFRKDREPHB4ERBB2AURKA | |
| SCHEMBL174651 | 1.00 | EGFR (0.70) | EGFRKDREPHB4ERBB2AURKA | |
| SCHEMBL29623753 | 1.00 | EGFR (0.70) | EGFRKDREPHB4ERBB2AURKA | |
| SCHEMBL208538 | 1.00 | EGFR (0.70) | EGFRKDREPHB4ERBB2AURKA | |
| SCHEMBL375151 | 0.94 | EGFR (0.63) | EGFRKDREPHB4ERBB2AURKA | |
| SCHEMBL2781493 | 0.94 | EGFR (0.63) | EGFRKDREPHB4ERBB2AURKA | |
| SCHEMBL12743520 | 0.94 | EGFR (0.68) | EGFRKDREPHB4ERBB2AURKA | |
| SCHEMBL1446761 | 0.93 | EGFR (0.69) | EGFRKDREPHB4ERBB2AURKA | |
| SCHEMBL1446416 | 0.93 | EGFR (0.69) | EGFRKDREPHB4ERBB2AURKA | |
| SCHEMBL1446759 | 0.93 | EGFR (0.69) | EGFRKDREPHB4ERBB2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 809 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281860-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-17 | — | — | US | claimed |
| US-20100099651-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | claimed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | claimed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | claimed |
| EP-1901776-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | Boehringer Ingelheim International GmbH (DE) | 2008-03-26 | — | — | EP | claimed |
| EP-1781298-A1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-05-09 | — | — | EP | claimed |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | US | claimed |
| WO-2007003554-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE. | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | claimed |
| US-20060178364-A1 | Use of EGFR tyrosinkinase inhibitors for treatment of chronic rhinosinusitis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-10 | — | — | US | claimed |
| EP-1651228-A1 | USE OF QUINAZOLINE TYROSINE KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY PROCESSES | Boehringer Ingelheim International GmbH (DE) | 2006-05-03 | — | — | EP | claimed |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | claimed |
| WO-2005102349-A1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | claimed |
| US-20050059661-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-17 | — | — | US | claimed |
| WO-2005011701-A1 | USE OF QUINAZOLINE TYROSINE KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-10 | — | — | WO | claimed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| EP-1492536-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | disclosed |
| WO-2003082290-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099651-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, GRK5, PRKCH | EGFR 63/4885KDR 604/4885EPHB4 182/4885 |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | ADRB2, ADRA2A, ADRB1 | EGFR 4088/4885KDR 3597/4885EPHB4 3096/4885 |
| US-20110281860-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | EGFR, ERBB4, GRK5 | EGFR 1/4885KDR 838/4885EPHB4 473/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | EGFR 53/4885KDR 436/4885EPHB4 195/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | EGFR 3691/4885KDR 4444/4885EPHB4 2716/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | EGFR 591/4885KDR 4638/4885EPHB4 2922/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | EGFR 1752/4885KDR 514/4885EPHB4 756/4885 |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BDKRB2, EDNRB, GRK5 | EGFR 53/4885KDR 436/4885EPHB4 195/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | EGFR 221/4885KDR 1724/4885EPHB4 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.